

November 05, 2025

The BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051.

Scrip Code: 541540, 890202

Symbol: SOLARA, SOLARAPP1

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform you that the Board of Directors of the Company at their meeting held today i.e., Wednesday, the November 05, 2025 have interalia, considered and approved the following items:

1. Appointment of Mr. Sarat Kumar Asuri, Chief Financial Officer of the Company, as the Chief Investor Relations Officer (CIRO).
2. Revision in remuneration of Mr. Mohan Muthunarayanan, Whole-time Director (DIN: 03610282) of the Company, within the limits already approved by the shareholders and in line with the Company’s Remuneration Policy.
3. Revision in the remuneration of the eligible Senior Management Personnels.
4. The existing Risk Management Policy of the Company has been reviewed and confirmed

This is for your information and records.

Thanking you,

Yours faithfully,

For Solara Active Pharma Sciences Limited

Pooja Jayakumar
Company Secretary & Compliance Officer
Membership No.: A57415